During the therapeutic phase, the expression levels of miRNAs and related genes (TNFAIP1, TFG-βRII and IL-1β) were significantly downregulated except for IL-4 after the administration of various treatments demonstrating their high efficacy in minimizing the effects of AD. This evidence concerns the gene TNFAIP1 and Alzheimer disease.